[ad_1]
As part of an experiment conducted in 33 countries of the world on more than 17,000 patients with type 2 diabetes and cardiovascular disease, the team administered to half of the participants dabagliphlozine, while the Another half received a placebo. The team followed the participants for four years, during which 13% of participants had heart failure.
In contrast, the researchers found that patients taking this drug presented a risk of death from heart disease and heart failure reduced by 41 to 45% compared to placebo. They also found that people who took the medication had reduced their chances of hospitalization due to heart failure or other heart disease at 38%.
Heart failure patients usually lose their ability to pump blood properly. Thus, the body 's organs are not supplied with abundant amounts of blood and oxygen, resulting in a constant sensation of exhaustion and fatigue. Symptoms also include a feeling of shortness of breath when climbing a staircase, for example a decrease in the ability to exert effort, or a general state of weakness.
According to the World Health Organization, cardiovascular disease is the leading cause of death in the world, with more deaths than any other cause of death.
This article is intended for heart patients, a diabetes medicine that surrounds blood vessels and comes from the site of Lebanon 24 and does not reflect in any way the policy of the site or the point of view of the person.
[ad_2]
Source link
